Bio & Pharma
Clinomics releases equipment that quickly finds lung cancer mutations
The device needs just 10 ml of whole blood to automatically conduct three key processes to achieve its goal
By Jul 21, 2023 (Gmt+09:00)
1
Min read
Most Read
Macquarie eyes its 1st Korean data center valued around $722 mn
SK Inc. in talks to sell Pharmteco’s US CDMO plant to Novo Nordisk
S.Korea's LS Materials set to boost earnings ahead of IPO process
Galaxy Ring, new foldables set to steal the show at Samsung Unpacked Paris
POSCO gears up for carbon-free steelmaking with hydrogen
Clinomics, a South Korean biotech company specializing in liquid biopsies, on Thursday said it developed equipment that can detect four types of lung cancer-causing epidermal growth factor receptor, or EGFR, gene mutations within three hours.
The machine improves user convenience by automatically separating plasma and filtering out cell-free DNA when whole blood is added, it added.
The company’s One-Stop All-In-One System automatically separates blood components and nucleic acids from 10 ml of whole blood.
This equipment was jointly developed with Asan Medical Center in Seoul and the Cheonan, South Chungcheong Province-based Korea Institute of Industrial Technology. Clinical research done at Asan found sensitivity of 90% and specificity 85% compared to a biopsy.
In the second half of this year, Clinomics will submit a clinical trial protocol to the Ministry of Food and Drug Safety, with clinical trials planned at Asan.
Write to Jeong Min Nam at peux@hankyung.com
The machine improves user convenience by automatically separating plasma and filtering out cell-free DNA when whole blood is added, it added.
The company’s One-Stop All-In-One System automatically separates blood components and nucleic acids from 10 ml of whole blood.
This equipment was jointly developed with Asan Medical Center in Seoul and the Cheonan, South Chungcheong Province-based Korea Institute of Industrial Technology. Clinical research done at Asan found sensitivity of 90% and specificity 85% compared to a biopsy.
In the second half of this year, Clinomics will submit a clinical trial protocol to the Ministry of Food and Drug Safety, with clinical trials planned at Asan.
Write to Jeong Min Nam at peux@hankyung.com
More to Read
-
Corporate strategyHyundai Glovis to spend $6.5 billion, seek M&As for expansion
Jun 28, 2024 (Gmt+09:00)
-
Korean chipmakersSouth Korea sets sights on fostering EDA tech to win HBM chip war
Jun 28, 2024 (Gmt+09:00)
Comment 0
LOG IN